ClinicalTrials.gg
Active, not recruitingNCT04430257PrEPUpdated Oct 13, 2026

Pre-exposure Prophylaxis (PrEP) for Health

An interventional study of HIV and PrEP education and Motivational interviewing in Substance Dependence and HIV (Human Immunodeficiency Virus), sponsored by Brown University. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Brown University · Not applicable, Interventional, and Prevention

How we know

Updated Oct 13, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 18 studies in Substance-Related Disorders by Brown University — 3 open to participants now, 6 under way, none of them phase 3. Substance-Related Disorders · Brown University.

Planned enrollment
7th of 18
200 · median 131
Started
2021
the only one that year
No phase
14 of 18
3 open now
Registered
12th of 18
by date

Among the 18 studies in Substance-Related Disorders by Brown University, this one is the 7th largest by planned enrollment, is the only one that started in 2021, is one of 14 with no phase, and was the 12th registered.

Substance-Related Disorders

2,242 studies on the registry are indexed under Substance-Related Disorders; 408 are open to participants now.

Browse Substance-Related Disorders studies →

Open to participants now

3 of the 18 studies in Substance-Related Disorders by Brown University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 266 Substance-Related Disorders studies recruiting now, 130 (49%) set no upper age limit and 117 (44%) stop at 75 or younger; 55 take children under 18; 90 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Substance-Related Disorders by Brown University, or all of them as a file.
02

Study summary

This randomized controlled trial will test the efficacy of "PrEP for Health," a behavioral intervention to improve the use of antiretroviral pre-exposure prophylaxis (PrEP) among at-risk people who inject drugs (PWID) in two syringe service program (SSP) settings in Lawrence and Boston/Cambridge, Massachusetts. The investigators will equally randomize 200 PWID to receive either (a) the "PrEP for Health" intervention condition involving theory-informed HIV and PrEP education, motivational interviewing, problem-solving and planning, and ongoing patient navigation (n=100), or (b) the standard of care condition involving PrEP information and referrals (n=100). Successful PrEP uptake (via medical/pharmacy records), post-treatment PrEP adherence (assessed at 3 months via drug levels in hair), and longer-term PrEP adherence (assessed at 6 and 12 months via drug levels in hair) will be evaluated. The degree to which intervention efficacy occurs through specific conceptual mediators and differs according to hypothesized moderators will also be evaluated.

Read the detailed description

The overall goal of this proposal is to evaluate the efficacy of the "PrEP for Health" navigator delivered behavioral intervention in improving PrEP uptake (via medical/pharmacy records), post-treatment PrEP adherence (assessed at 3 months via drug levels in hair), and longer-term PrEP adherence (assessed at 6 and 12 months via drug levels in hair) among PWID in SSPs. Eligible PWID (n=200 total; 100 recruited from each study site) will be equally randomized to an active PrEP for Health intervention arm (n=100) or a Standard of Care control condition (n=100). Assessments will be conducted at baseline and 1, 3, 6, and 12 months after randomization.

We hypothesize that brief, multi-component behavioral intervention sessions with ongoing support delivered by trained PrEP Navigators within Syringe Service Programs (SSPs) will improve PrEP uptake, adherence, and long-term adherence in PWID by increasing HIV and PrEP knowledge (including alleviating concerns about side effects), increasing HIV risk perceptions and PrEP interest and motivation, improving PrEP use self-efficacy and behavioral skills, and reducing structural barriers over time. Based on our formative research, we also hypothesize that the strength of intervention effects may differ by key individual characteristics (age, gender, baseline sexual risk, polysubstance, and stimulant use).

This is a randomized control trial (RCT). Participants will be recruited via outreach specialist at SSP sites and during routine community outreach practices of the organizations. After eligibility confirmation and baseline assessments, participants will be randomized to one of two study arms: 1) Standard of Care (SOC) Control Condition: as routinely provided through the SSP study sites, participants will receive information and services according to routine practice and a brief video that describes what PrEP is and how it works to prevent HIV via sexual and injection transmission; 2) "PrEP for Health" Intervention Condition: a trained PrEP Navigator will deliver a manualized PrEP uptake and adherence intervention in private counseling rooms at SSPs followed by 3 months of additional PrEP navigation support through in-person, phone, and text interactions as needed. Participants will complete a total of four follow-up visits over a 12-month period. Participants who initiate PrEP will have a hair sample collected at 3-, 6-, and 12-month visits. All participants will receive a rapid HIV screening test at 12-month follow-up.

03

Conditions studied

  • Substance Dependence
  • HIV (Human Immunodeficiency Virus)

Keywords

  • PrEP (pre-exposure prophylaxis )
  • PWID (people who inject drugs)
  • SSP (syringe service program)
  • HIV education
  • Motivational interviewing
  • Self efficacy
  • Social cognitive theory
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -uninfected (verified by rapid/4th generation test)
  • Reporting past-month injection of any drugs
  • One or more HIV risk behaviors (past-month receptive syringe sharing, transactional sex, or condomless sex with an HIV-infected or unknown-status partner)
  • Not currently on and never taken PrEP
  • Able to understand and speak English or Spanish

Exclusion criteria

Exclusion Criteria:

  • Unable to provide due to severe mental or physical illness, cognitive impairment, or substance intoxication at the time of enrollment
  • Living in Massachusetts (MA) for \<3 months
  • Planning to move out of MA within a year
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    PrEP for health

    Participants in the PrEP (pre-exposure prophylaxis) for health arm will receive theory informed HIV and PrEP education, motivational interviewing, problem-solving and planning, and ongoing patient navigation.

    Other: HIV and PrEP education · Behavioral: Motivational interviewing · Behavioral: Problem-solving and planning · Behavioral: Patient navigation · Other: PrEP information

  • Active comparator
    Standard of care

    Participants in the standard of care arm will receive PrEP information and referrals.

    Other: PrEP information · Other: Referrals

Interventions

  • OtherHIV and PrEP education

    Navigators will deliver Social Cognitive Theory-informed HIV and PrEP education.

  • BehavioralMotivational interviewing

    Bachelors-level PrEP Navigators who are trained in motivational interviewing (MI) will use MI to promote the behavioral intervention.

  • BehavioralProblem-solving and planning

    Bachelors-level PrEP Navigators will assist participants with problem-solving and planning.

  • BehavioralPatient navigation

    Ongoing PrEP navigation support to promote participants' initial and continued engagement with PrEP clinics affiliated with the two study sites

  • OtherPrEP information

    A brief video that describes what PrEP is and how it works to prevent HIV via sexual and injection transmission will be shown to participants.

  • OtherReferrals

    Study staff will provide basic information about PrEP and referrals to PrEP clinicians.

06

What researchers measure

Primary outcomes

  1. PrEP uptake

    PrEP uptake will be assessed via medical/pharmacy records

    Time frame: 3 months

  2. Post-treatment PrEP adherence

    PrEP adherence will be assessed by drug levels in hair samples at the acute follow up time point (3 months post-baseline)

    Time frame: 3 months

Secondary outcomes

  1. Longer-term PrEP adherence

    Longer-term PrEP adherence will be assessed by drug levels in hair samples at 6 and 12-month post-baseline

    Time frame: 6 and 12 months

07

Study locations

2 sites
  • AIDS Action
    Cambridge, Massachusetts 02139, United States
  • Greater Lawrence Family Health Center
    Lawrence, Massachusetts 01841, United States
08

References and documents

Publications

  • Bazzi AR, Bordeu M, Baumgartner K, Sproesser DM, Bositis CM, Krakower DS, Mimiaga MJ, Biello KB. Study protocol for an efficacy trial of the "PrEP for Health" intervention to increase HIV PrEP use among people who inject drugs. BMC Public Health. 2023 Mar 17;23(1):513. doi: 10.1186/s12889-023-15429-w. PubMed 36932369 ↗

Individual participant data

Plan to share: Yes — By request to the study investigators

Time frame: Data will be available after the study has closed and after publication of the primary study findings.

Access criteria: Requests will be reviewed by the principal investigators.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Jun 2026, 57 months.

Of 819 non-industry interventional studies with no phase under Substance-Related Disorders, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 53. This study's 57 months is above that.

Counting every sponsor, half of 859 studies reached it within 34 months; a quarter within 17 and three quarters within 53.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion May 2026 → Jun 2026 and completion May 2026 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2020
First posted
Jun 12, 2020
StartActual
Sep 2, 2021
Primary completionActual
Jun 16, 2026was May 2026
CompletionEst.
Nov 2026was May 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 13, 2026
Primary completion
May 15, 2026→Jun 16, 2026 (actual)
Oct 13, 2026
Study completion
May 15, 2026→Nov 2026
Oct 13, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 36932369 ↗
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Recruiting→Active, not recruiting
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 36932369 ↗
    Primary completion May 15, 2026→Jun 16, 2026 (now actual)
    Study completion May 15, 2026→Nov 2026
    + 5 other changes: verification date, oversight details, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04430257
Lead sponsor
Brown University
Collaborators
National Institute on Drug Abuse (NIDA), The Fenway Institute, AIDS Action Committee of Massachusetts, Greater Lawrence Family Health Center, University of California, San Diego, Beth Israel Deaconess Medical Center
Responsible party
Sponsor
First posted
Jun 12, 2020
Start date
Sep 2, 2021
Primary completion
Jun 16, 2026
Completion
Nov 2026 (estimated)
Last update
Oct 13, 2026

Study contacts

Katie Biello, PhD, MPH
principal investigator · Brown University
Angela Bazzi, PhD, MPH
principal investigator · University of California, San Diego

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion